Latest Revenue Guidance News

CurveBeam AI has raised A$1.75 million through an oversubscribed SPP shortfall offer and placement, lifting its recent capital raised to A$7.36 million. The funds will support the HiRise China launch, product development, supply-chain preparation and working capital.

Lumos Diagnostics has increased live FebriDx sites to 215 and moved two additional top 100 US urgent care groups into network rollout across more than 40 sites. Two further health-system-owned groups are validating the test across more than 45 sites, but the announcement does not disclose contract values or guaranteed purchase volumes.

Sparc Technologies has reported a 25% reduction in corrosion creep after adding HydroGraph’s Fractal Graphene to its ecosparc protective coating. The result strengthens the commercial case, but a definitive supply agreement remains conditional on longer testing due in November.

CurveBeam AI has secured FDA 510(k) clearance for CT-based bone mineral density measurement, establishing the first regulatory step towards a potential new SaaS offering. The more commercially significant HiRise weight-bearing application still requires a separate clearance.

Synertec has identified ANSTO as the client behind its $45.5 million engineering contract, with about $36 million of revenue expected during the first 26 months. The project could improve FY27 revenue, but the company has not yet revised its guidance.

Proteomics International has begun a controlled release of two Promarker diagnostic tests through Healius in Western Australia and the Northern Territory. National commercial sales are targeted for Q2 FY27, but uptake and revenue remain difficult to estimate at this early stage.

Synertec has landed a $45.5 million engineering services contract with an undisclosed Australian Government agency, locking in revenue visibility through FY35 and marking a major step in its infrastructure sector growth.

Synertec Corporation has reported its first positive net operating cash flow since FY19, underpinned by strong growth in recurring revenues and a landmark contract with Santos for its Powerhouse energy storage system.

Vmoto Limited posted its strongest half-year sales ever with $35.7 million revenue and a 140% surge in unit sales, underpinned by new global partnerships and international market growth.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Verbrec Limited accelerated its growth trajectory in FY2026, driven by a strategic acquisition and divestment, delivering a 52% revenue increase and a near tripling of net profit.

Electro Optic Systems (ASX:EOS) reported a record first half in 2026 with revenue soaring 283% to A$168.8 million, driven by the MARSS acquisition and expanding defence contracts. The order book jumped 84% to A$846 million, underpinning a bullish outlook amid a global defence spending surge.